Original title: late night suspense! Nearly four years after winning the Nobel Prize, Tu youyou will release another major scientific research breakthrough! Artemisinin may still be the protagonist. The list of concept stocks came late at night, and the whole network was swiped by a heavy news from Xinhua news agency.
Tu youyou's team will announce a major scientific research breakthrough on the 17th of this month, Xinhua reported. The client of Xinhua news agency released the news with a video and a poem. In the video, Tu Youyou, winner of the Nobel Prize in physiology or medicine, said: "once the malaria parasite becomes resistant to artemisinin combination therapy, there will be no cure for malaria, and mankind is bound to suffer a catastrophe." Wang Jigang, a researcher at the artemisinin research center of the Chinese Academy of traditional Chinese medicine, said: "without artemisinin, millions of people will die every year."
According to these descriptions, the major scientific research breakthrough to be released today may still be related to artemisinin!
In October 2015, Tu youyou became the first Chinese native scientist in history to win the Nobel Prize for science because of its discovery that artemisinin can effectively reduce the mortality of malaria patients. According to media reports, within two years after that, Tu youyou and her team started the research on the possible drug resistance mechanism of artemisinin, and found that dihydroartemisinin had a unique effect on lupus erythematosus. The researchers also proved that artemisinin has some effects in the treatment of tumors, leukemia, rheumatoid arthritis, multiple sclerosis, allergic diseases and so on.
Market analysts believe that if artemisinin research makes a major breakthrough, the traditional Chinese medicine sector represented by the concept of artemisinin in A-share listed companies will benefit. Among the listed companies, Fosun Pharmaceutical (23.280, -0.23, - 0.98%) maintained the first export volume of Artemisia annua antimalarial drugs in China, and Kunming Pharmaceutical Group (8.810, -0.35, - 3.82%), Zhejiang Pharmaceutical (10.470, -0.15, - 1.41%), XinHeCheng (19.790,0.10,0.51%), China Resources Shuanghe (12.160, - 0.13, - 1.06%), Baiyunshan (38.200, - 0.70, - 1.80%) may also benefit from it.
Tu youyou swipes the screen late at night
On the evening of June 16, a sudden news from Xinhua News Agency lifted the audience's appetite. According to Xinhua news agency, Tu youyou's team will announce a major scientific research breakthrough on the 17th. The report did not describe any major scientific breakthrough, but it was accompanied by a poem and a video.
In the video, Tu Youyou, winner of the Nobel Prize in physiology or medicine, said that once the malaria parasite becomes resistant to artemisinin combination therapy, there will be no cure for malaria and mankind is bound to suffer a catastrophe. In addition, Wang Jigang, a researcher at the artemisinin research center of the Chinese Academy of traditional Chinese medicine, said that without artemisinin, millions of people would die every year.
What kind of breakthrough will it be
What kind of 'hot money' will this be? The outside world doesn't know! Many people who care about this may have a sleepless night. However, according to previous media reports, this breakthrough may still be related to artemisinin.
In October 2015, Tu youyou became the first Chinese native scientist in history to win the Nobel Prize for science because of its discovery that artemisinin can effectively reduce the mortality of malaria patients. After that, she did not stop her research on artemisinin.
According to Xinhua Daily Telegraph, within two years of winning the Nobel Prize, Tu youyou's team officially published 15 scientific research papers, including two important papers with more than 10 influencing factors, three patents are under application, and the research on the possible drug resistance mechanism of artemisinin has also been started. Tu youyou's team also found in-depth research that dihydroartemisinin has a unique effect on lupus erythematosus. According to the existing clinical trials, artemisinin has an effective rate of more than 90% for discoid lupus erythematosus and more than 80% for systemic lupus erythematosus. The researchers also proved that artemisinin has some effects in the treatment of tumors, leukemia, rheumatoid arthritis, multiple sclerosis, allergic diseases and so on.
At that time, Tu youyou said, "if we understand the antimalarial mechanism of artemisinin, we can give full play to its efficacy and better apply the drug. This is an important link in artemisinin research. Figuring out the 'secret' of artemisinin may not only play its anti malaria role. " Tu youyou told reporters at that time that she had seen the "hope of artemisinin in expanding indications".
There are various indications that Tu youyou's research breakthrough may still involve the potential of artemisinin.
These stocks may benefit
If Tu youyou's new breakthrough is still related to artemisinin, artemisinin concept stocks may benefit from it. In fact, as early as Tu youyou won the Nobel Prize, these stocks reacted. According to the data summarized at that time, the following companies are related to artemisinin:
Fosun Pharmaceutical: the holding subsidiary Guilin Nanyang pharmaceutical artesunate officially passed the who-pq certification in 2010. Artesunate is included in 3 of the 5 compounds recommended by who. The innovative drug artesun (artesunate for injection) is the first in the world and has become the first choice for the treatment of severe malaria strongly recommended by who. In 2014, the sales of Fosun artesunate drugs exceeded 200 million yuan.
Kunming Pharmaceutical Group: Kunming Pharmaceutical is the supplier of raw materials of Novartis artemether and has the production approval of artemether injection. On September 29, 2015, after the acquisition of China Ketai, Kunming Pharmaceutical obtained artemisinin products such as dihydroartemisinin piperaquine tablets. At present, Kunming drug artemether injection and dihydroartemisinin piperaquine tablets (ketaifu) are applying for who-pq certification. At the end of 2018, Kunming Pharmaceutical Group, bill and Melinda & middot; The Gates Foundation (hereinafter referred to as the 'Foundation') signed the 'who pre certification cooperation agreement for ketaifu (dihydroartemisinin piperaquine phosphate) of Kunming Pharmaceutical Group'.
Zhejiang Pharmaceutical: the supplier of benflumetol, the component of Novartis Coartem (artemether + benflumetol), with the approval of artemether raw materials.
XinHeCheng: it has the approval documents for artesunate preparation and raw materials and dihydroartemisinin preparation.
China Resources Shuanghe: it has the approval of dihydroartemisinin preparation.
Baiyun Mountain: there are artemisinin approvals. Solemnly declare: the purpose of Dongfang fortune (12.510, - 0.39, - 3.02%) to publish this information is to spread more information, which has nothing to do with the position of this website.